{"totalCount":3,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07105254","orgStudyIdInfo":{"id":"20251829"},"organization":{"fullName":"Derm Texas, PLLC","class":"NETWORK"},"briefTitle":"An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)","officialTitle":"An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)"},"statusModule":{"statusVerifiedDate":"2025-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-08-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-05-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-14","studyFirstSubmitQcDate":"2025-07-29","studyFirstPostDateStruct":{"date":"2025-08-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-08-05","lastUpdatePostDateStruct":{"date":"2025-08-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Derm Texas, PLLC","class":"NETWORK"},"collaborators":[{"name":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)"},"conditionsModule":{"conditions":["Non-segmental Vitiligo"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":20,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%","type":"EXPERIMENTAL","interventionNames":["Drug: Roflumilast topical 0.3% foam"]}],"interventions":[{"type":"DRUG","name":"Roflumilast topical 0.3% foam","description":"Roflumilast 0.3% topical foam","armGroupLabels":["Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The primary endpoint of this study is the number patients achieving F-VASI 50.","description":"The number of patients achieving a 50% improvement in their facial Vitiligo Area \\& Severity Index score (F-VASI 50) at week 24.","timeFrame":"Week 24"}],"secondaryOutcomes":[{"measure":"- Percentage of patients achieving: T-VASI50, T-VASI75, T-VASI90, and T-VASI100; F-VASI75, F-VASI90, and F-VASI100 at 24 weeks. Patient Assessments of - Patient Global Impression of Change-Vitiligo (PaGIC-V) - Vitiligo Noticeability Scale (VNS)","description":"The percentage of patients who achieve improvements of 50%, 75%, 90% and100% from baseline to week 24 in their facial and total VASI scores. (F-VASI-50, 75, 90, 100 \\& T-VASI-50, 75, 90, 100). Patients will assess their impression of vitiligo change and noticeability over the course of the study.","timeFrame":"Baseline, the at weeks 4, 8, 12, 18 & 24."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female subjects aged 2 years but less than 18 years\n2. Pediatric and adolescent subjects: Informed consent of parent(s) or legal guardian, and, if age appropriate, assent by the subjects, as required by local laws.\n3. Diagnosis of non-segmental vitiligo based on clinical history and dermatology examination for at least 3 months.\n4. Diagnosis of non-segmental vitiligo with the following:\n\n   1. BSA affected \\< 10% AND\n   2. At least 0.5% BSA affected on the face. AND\n   3. Pigmented hair within some of the areas of vitiligo on the face\n5. In good health as judged by the Investigator, based on the medical history, and dermatology examination.\n6. Subjects and parent(s)/legal guardian (s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any serious medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator.\n2. Subjects with known or suspected:\n\n   1. Severe renal insufficiency\n   2. Moderate to severe hepatic disorders (Child-Pugh B or C)\n   3. Subjects who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study, including (any biologic or experimental therapy within 12 weeks (or 5 half-lives), phototherapy within 4 weeks, immunomodulating treatments within 4 weeks, or topical treatments within 1 week.\n3. Subjects who are unwilling to refrain from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline/Day 1 and during the study.\n4. Subjects with diagnosis of other forms of vitiligo (e.g. Segmental), other differential diagnosis of vitiligo or other skin depigmentation disorders (e.g. Piedbaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor) that would interfere with the evaluations of the effect of the study medication, as determined by the Investigator.\n5. Subjects with known genetic dermatological conditions that overlap with non-segmental vitiligo.\n6. Known allergies to excipients in Roflumilast foam (petrolatum, isopopyl palmitate, methylparaben, propylparaben, diethylene glycol monomethyl ether, hexylene glycol, cetylseteary alcohol, dicetyl phosphase and ceteth-10 phosphate)\n7. Subjects who cannot discontinue systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously (e.g. Erythromycin, ketoconazole, fluvoxamine, enoxacin, cimetidine)\n8. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline/Day 1.\n9. Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.\n10. Previous treatment with Roflumilast cream or foam for vitiligo in the past 3 months.\n11. Parent (s)/legal guardians (s) who are unable to communicate, read, or understand the local language (s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.\n12. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Amanda Harvey, Study Coordinator","role":"CONTACT","phone":"2148456426","email":"aharvey@derm-texas.com"}],"overallOfficials":[{"name":"Kelly Warren, MD","affiliation":"Derm Texas, PLLC","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Derm Texas","status":"RECRUITING","city":"Dallas","state":"Texas","zip":"75235","country":"United States","contacts":[{"name":"Amanda Study Coordinator","role":"CONTACT","phone":"214-845-6426","email":"aharvey@derm-texas.com"},{"name":"Kelly Warren, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.78306,"lon":-96.80667}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"interventionBrowseModule":{"meshes":[{"id":"C424423","term":"Roflumilast"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07340216","orgStudyIdInfo":{"id":"ARQ-154-127"},"organization":{"fullName":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis","officialTitle":"An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% Administered QD in Pediatric Participants With Scalp and Body Psoriasis"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-12-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-19","studyFirstSubmitQcDate":"2026-01-05","studyFirstPostDateStruct":{"date":"2026-01-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-05","lastUpdatePostDateStruct":{"date":"2026-01-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.","detailedDescription":"ARQ-154-127 is a Phase 1, open-label, single arm, maximum usage pharmacokinetic and safety study of roflumilast foam 0.3% in participants with scalp and body psoriasis.\n\nThe goal of the study is to:\n\n* Evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile of ARQ-154 foam 0.3%.\n* Assess the safety and tolerability of ARQ-154 foam 0.3%"},"conditionsModule":{"conditions":["Psoriasis"],"keywords":["Scalp and Body Psoriasis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":16,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ARQ-154 Foam 0.3%","type":"EXPERIMENTAL","description":"ARQ-154 foam 0.3% will be applied QD. Treatment duration will be up to 6 weeks, including 2 weeks under maximal usage conditions, followed by an optional 4 weeks under non-maximal usage conditions.","interventionNames":["Drug: ARQ-154 Foam 0.3%"]}],"interventions":[{"type":"DRUG","name":"ARQ-154 Foam 0.3%","description":"ARQ-154 Foam 0.3%","armGroupLabels":["ARQ-154 Foam 0.3%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Concentration of Roflumilast and Roflumilast N-Oxide from plasma","description":"Assessment of steady-state trough plasma concentrations after 2 weeks of study drug administration.","timeFrame":"2 Weeks"},{"measure":"Participant incidence of adverse events","description":"Number of participants with adverse events during treatment will be assessed","timeFrame":"6 Weeks"},{"measure":"Incidence of application site reactions","description":"Number of participants that experience an application site skin reaction by investigator assessment and participant assessment will be assessed","timeFrame":"6 Weeks"},{"measure":"The incidence of changes from Baseline in the total Children's Depression Inventory 2 (CDI-2)score.","description":"The CDI-2 is an assessment instrument used to evaluate the severity of depressive symptoms in children.","timeFrame":"6 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females, ages 2 years to \\< 12 years old at Day 1.\n* Clinical diagnosis of psoriasis vulgaris of at least 2 months duration at Screening as determined by the Investigator.\n* Scalp psoriasis with an Investigator Global Assessment (S-IGA) of scalp disease severity of at least Moderate ('3') at Day 1.\n* An IGA of body (non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Day 1.\n* Extent of scalp psoriasis involving ≥ 10% of the total scalp at Day 1.\n* Body psoriasis (non-scalp) involving at least 3% BSA on Day 1.\n\nExclusion Criteria:\n\n* Participants who cannot discontinue medications and treatments prior to Day 1 (first application of IP).\n* Current diagnosis of non-plaque forms of psoriasis. Current diagnosis of drug-induced psoriasis.\n* Participants who have significant active systemic or localized infection or have had any infection that required oral or intravenous administration of antibiotics, antifungal or antiviral agents within 7 days prior to Day 1.\n* Participants with skin conditions other than psoriasis vulgaris that would interfere with evaluations of the effect of the study medication, as determined by the Investigator.\n* Participants who cannot discontinue the use of strong cytochrome P-450 CYP3A4 inhibitors for 2 weeks prior to Day 1 and during the study period.\n* A medical history of severe renal insufficiency, moderate to severe hepatic disorders (e.g., Child-Pugh B or C), or chronic infectious disease (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus \\[HIV\\]).\n* Participants who are family members of the clinical study staff or sponsor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"12 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"centralContacts":[{"name":"Arcutis Biotherapeutics","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"locations":[{"facility":"Arcutis Clinical Study Site 106","status":"RECRUITING","city":"Bryant","state":"Arkansas","zip":"72022","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"1-844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":34.59593,"lon":-92.48905}},{"facility":"Arcutis Clinical Study Site 107","status":"RECRUITING","city":"Miami Lakes","state":"Florida","zip":"33014","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":25.90871,"lon":-80.30866}},{"facility":"Arcutis Clinical Study Site 108","status":"RECRUITING","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Arcutis Clinical Study Site 105","status":"RECRUITING","city":"West Lafayette","state":"Indiana","zip":"47906","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":40.42587,"lon":-86.90807}},{"facility":"Arcutis Clinical Study Site 104","status":"RECRUITING","city":"Arlington","state":"Texas","zip":"76011","country":"United States","contacts":[{"name":"Arcutis Biotherapeutics, Inc.","role":"CONTACT","phone":"844-692-6729","email":"studyinquiry@arcutis.com"}],"geoPoint":{"lat":32.73569,"lon":-97.10807}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D011565","term":"Psoriasis"}],"ancestors":[{"id":"D017444","term":"Skin Diseases, Papulosquamous"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07077902","orgStudyIdInfo":{"id":"2020-527"},"organization":{"fullName":"Tulane University","class":"OTHER"},"briefTitle":"A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa","officialTitle":"An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis."},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-09-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-11","studyFirstSubmitQcDate":"2025-07-11","studyFirstPostDateStruct":{"date":"2025-07-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-19","lastUpdatePostDateStruct":{"date":"2025-12-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Tulane University","class":"OTHER"},"collaborators":[{"name":"Arcutis Biotherapeutics, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a phase 2a, open label study.\n\nAs psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.","detailedDescription":"With limited topical treatment options available for mild HS and for flare control, the investigators hypothesize that topical roflumilast, a phosphodiesterase-4 inhibitor (PDE4) inhibitor, is a safe and efficacious monotherapy or add-on therapy in HS patients.\n\nThe study will investigate the efficacy, safety, and toxicity of topical roflumilast 0.3% foam applied to affected areas once a day as monotherapy in Hurley stage I HS patients and as add-on therapy with daily application for Hurley stage II and III HS patients on 4 months of stable treatment regimen via changes in gene expression compared to pre-treatment using Ribonucleic acid (RNA) derived from tape strip collection."},"conditionsModule":{"conditions":["Hidradenitis Suppurativa"],"keywords":["Topical roflumilast","Inflammatory skin condition","Painful nodules and abscesses in axilla and groin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":10,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"HS patients arm","type":"EXPERIMENTAL","description":"Patients must have a diagnosis of HS based upon the clinical criteria of a history of more or equal than 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time.\n\nPatients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.","interventionNames":["Drug: Topical roflumilast 0.3% foam"]}],"interventions":[{"type":"DRUG","name":"Topical roflumilast 0.3% foam","description":"Topical roflumilast is a potent phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis, seborrheic dermatitis and atopic dermatitis","armGroupLabels":["HS patients arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Measure the change in gene expression profile at week 16 of using topical roflumilast vs baseline","description":"The investigators will perform gene expression profiling (GEP) using RNA sequencing on tape strips collected before and after treatment with topical roflumilast. Sixteen tape strips from lesional skin will be performed before treatment with topical roflumilast and after 4 months of treatment for gene expression profiling.","timeFrame":"Baseline, 16 weeks"}],"secondaryOutcomes":[{"measure":"Measure the overall response rate of topical roflumilast when applied to the skin of HS patients.","description":"The efficacy assessment will be based on overall response rate (ORR) of topical roflumilast in patients with HS at 4 months.\n\nThe ORR will be measured using the change in total abscess and inflammatory nodule count (AN count) at week 16 vs number of active lesions at baseline. Change from baseline will be calculated as the week 16 value minus the baseline value.","timeFrame":"Baseline, 4 months"},{"measure":"Measure the change in quality of life for HS patients applying topical roflumilast to their skin","description":"The investigators will assess the patients' quality of life using Dermatology Life Quality Index (DLQI) score ranging from (0-30) where 0 has no effect on quality of life and 30 has an extremely large effect on quality of life. DLQI will be measured at months 0, 1 and 4 months.\n\nThe minimal clinically important difference on the DLQI score is a change of 4.","timeFrame":"Baseline, 1 month, 4 months"},{"measure":"Measure the change in numerical pain score for HS patients applying topical roflumilast to their skin","description":"The investigators will assess the skin pain response using Numerical Rating Scale (NRS30). NRS an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable). NRS will be measured at months 0, 1 and 4 months.\n\nThe minimal clinically meaningful important difference on the NRS score is ≥30% reduction and ≥2-point reduction in skin pain from baseline.","timeFrame":"Baseline, 1 month, 4 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must understand the risks and the benefits/purpose of the study and provide signed and dated informed consent.\n* Must be 18 years at time of signing informed consent form.\n* Willing to participate in all required evaluations and procedures in the study including the ability to apply topical medication without difficulty.\n* Patients must have a diagnosis of HS based upon the clinical criteria of a history of more than or equal 5 typical lesions (erythematous papules, nodules, or abscesses) in flexural sites with a recurring nature over time.\n* Patients must be candidate for topical therapy defined by active Hurley stage I or Hurley stage II/III with active disease after an adequate trial of systemic antibiotics/hormonal/immunomodulatory or biologic therapy.\n* Patient is required to be on stable dose of concomitant therapy for at least 3 months before enrollment and throughout the study period.\n* Females of childbearing potential must have a negative urine pregnancy test at baseline visit and be on adequate contraception throughout the study time.\n\nExclusion Criteria:\n\n* Concomitant use of topical antibiotics, topical corticosteroids, resorcinol, benzoyl peroxide, vitamin D analogs, Hibiclens wash (except for emollients) within 1 week of enrollment.\n* Increasing or changing dosing for concurrent therapy agents within 90 days before study day 0 and during the study period.\n* History of any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major uncontrolled disease.\n* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.\n* Pregnant or breastfeeding.\n* Prior major surgery or major life-threatening medical illness within 2 weeks.\n* Active hepatitis B or C infection with detectible viral nucleic acid in the blood or known Human Immunodeficiency Virus (HIV) positivity.\n* Patients with known active malignancy.\n* Any severe systemic illness requiring Intravenous (IV) antibiotics within the two weeks prior to initiation of the study drug.\n* Active substance abuse or a history of substance abuse within 6 months prior to screening.\n* Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Carole Bitar, MD","role":"CONTACT","phone":"504-988-5114","email":"cbitar@tulane.edu"},{"name":"Edward Coleman, MS","role":"CONTACT","phone":"504-988-5135","email":"ecoleman@tulane.edu"}],"overallOfficials":[{"name":"Carole Bitar, MD","affiliation":"Tulane University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Lakeview Hospital","status":"RECRUITING","city":"Covington","state":"Louisiana","zip":"70433","country":"United States","contacts":[{"name":"Carole Bitar, MD","role":"CONTACT"},{"name":"Carole Bitar, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":30.47549,"lon":-90.10042}},{"facility":"Lakeside Hospital","status":"RECRUITING","city":"New Orleans","state":"Louisiana","zip":"70001","country":"United States","contacts":[{"name":"Carole Bitar, MD","role":"CONTACT","phone":"504-988-5114","email":"cbitar@tulane.edu"},{"name":"Carole Bitar, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"LCMC Multi-speciality Clinic","status":"RECRUITING","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","contacts":[{"name":"Carole Bitar, MD","role":"CONTACT","phone":"504-988-5114","email":"cbitar@tulane.edu"},{"name":"Carole Bitar, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"University Medical Center","status":"RECRUITING","city":"New Orleans","state":"Louisiana","zip":"70112","country":"United States","contacts":[{"name":"Carole Bitar, MD","role":"CONTACT","phone":"504-988-5114","email":"cbitar@tulane.edu"},{"name":"Carole Bitar, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.95465,"lon":-90.07507}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D017497","term":"Hidradenitis Suppurativa"}],"ancestors":[{"id":"D017192","term":"Skin Diseases, Bacterial"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D012874","term":"Skin Diseases, Infectious"},{"id":"D013492","term":"Suppuration"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D016575","term":"Hidradenitis"},{"id":"D013543","term":"Sweat Gland Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C424423","term":"Roflumilast"}]}},"hasResults":false}
]}